Foxo Technologies Inc. CEO Seamus Lagan Provides Mid-year Update to Shareholders

FOXO shows operational progress, but most upside depends on unproven, capital-intensive future plans.

What the company is saying

FOXO Technologies Inc. is positioning itself as a diversified healthcare platform, emphasizing recent acquisitions and operational improvements as the foundation for future growth. The company claims its mid-2024 and late-2025 acquisitions have created a 'diverse, synergistic portfolio' that offers both stability and growth opportunities, though it does not provide hard evidence for these synergies. Management highlights a focus on optimizing operations and resolving corporate-level issues, asserting that these challenges are now behind them. The announcement spotlights headline financial improvements—specifically, a jump in quarterly net revenues to $5.1 million and a sharp reduction in operating losses to $0.3 million—while also touting high occupancy and rising admissions at Myrtle Recovery Centers. FOXO is explicit about its forward-looking ambitions: it is actively considering further acquisitions, plans to up-list its shares to a major exchange, and expects a potential Vector BioSource acquisition to add over $10 million in annual revenue if completed. The company also details capital structure maneuvers, including a 1:3,000 reverse stock split and the exchange of $7.8 million in preferred stock for debt, framing these as steps to attract institutional investors and reduce dilution. Notably, the company granted an exclusive IP license to LongevityFP Technologies, LLC, owned by former CEO Jon Sabes, with a capped royalty arrangement, but provides no detail on the commercial prospects or timing. The tone is upbeat and confident, with management projecting optimism about overcoming capital constraints and achieving self-sustainability, but the communication style leans heavily on aspirational and conditional language. Among notable individuals, Seamus Lagan is identified as CEO, and Jon Sabes as former CEO and related-party licensee; their involvement signals continuity but does not guarantee external validation or institutional backing. Overall, the narrative is crafted to reassure investors of operational momentum while inviting them to buy into a vision of imminent scale and capital market legitimacy.

What the data suggests

The disclosed numbers show tangible operational improvement in the most recent quarter. Net revenues for the three months ended March 31, 2026 were approximately $5.1 million, up from $3.2 million in the same period of 2025—a 59% increase. The loss from operations narrowed dramatically, from $1.5 million to $0.3 million, indicating better cost control or improved margin, though no segment breakdown is provided. Myrtle Recovery Centers' average daily census surged to 27.6 (92% occupancy) from 7.4 (25% occupancy) in 2024, and annualized patient admissions are projected at 700 for 2026, up from 195 in 2024 and 566 in 2025, suggesting strong demand and improved utilization. Scott County Community Hospital is projected to see 400 inpatient admissions and 65 swing bed admissions in 2026, up from 313 and 37, respectively, in 2025, but ER and outpatient visits are expected to decline slightly. The company claims the hospital generates 80% or more of total revenue, but does not provide a detailed segment breakdown or margin analysis. There is no full balance sheet, cash flow statement, or disclosure of net income, EBITDA, or liquidity position, limiting the ability to assess sustainability or capital adequacy. Several claims—such as improved efficiency, profitability, and the impact of acquisitions—are not supported by granular data. An independent analyst would conclude that while headline revenue and operational metrics are moving in the right direction, the lack of comprehensive financial disclosure and the absence of realized, bottom-line profitability make it difficult to fully validate the company's growth and value-creation narrative.

Analysis

The announcement presents a positive tone, highlighting revenue growth and reduced operating losses, both of which are supported by disclosed numerical data. However, many key claims are forward-looking, including intentions to pursue further acquisitions, up-list shares, and realize significant revenue from a potential acquisition that is not yet completed. Several statements about future growth, operational synergies, and improved profitability are aspirational and lack supporting evidence or binding commitments. The company references substantial capital actions (acquisitions, stock splits, debt exchanges) but does not provide immediate, quantifiable earnings impact from these moves. While operational improvements are evident, the absence of full profitability metrics (e.g., net income, EBITDA) and reliance on projections for major benefits limit the strength of the signal and elevate the hype level.

Risk flags

• ●Execution risk is high: The company's most significant growth drivers—such as the Vector BioSource acquisition and up-listing to a major exchange—are not completed and depend on successful negotiations, regulatory approvals, and capital raising. If these do not materialize, the projected revenue and valuation uplift will not occur.
• ●Capital intensity is substantial: FOXO's strategy relies on ongoing acquisitions and expansion, which require significant funding. The company admits to limited access to new capital in 2026, and future growth is explicitly contingent on securing additional financing. This exposes investors to dilution, debt risk, or stalled growth if capital markets are not receptive.
• ●Disclosure gaps limit transparency: While headline revenue and loss figures are provided, there is no full balance sheet, cash flow statement, or segment-level profitability data. This makes it difficult for investors to assess liquidity, leverage, or the true impact of acquisitions and operational changes.
• ●Forward-looking statements dominate: Over half of the key claims are projections or aspirations, not realized outcomes. This pattern increases the risk that management's optimism is not matched by future results, especially given the conditional language around major initiatives.
• ●Related-party transactions present governance risk: The exclusive IP license to LongevityFP Technologies, LLC, owned by former CEO Jon Sabes, creates potential conflicts of interest. While the royalty is capped, there is no disclosure of how the arrangement was priced or how it aligns with shareholder interests.
• ●Reverse stock split and preferred stock maneuvers may signal distress: The 1:3,000 reverse split and conversion of $7.8 million in preferred stock to debt are framed as positive, but such actions often reflect prior share price weakness or capital structure challenges. Investors should be wary of the underlying reasons for these moves.
• ●Dividend promises lack detail: The announcement of a 7.5% annual dividend on Series E Preferred Stock is not accompanied by cash flow data or payout history, raising questions about sustainability and actual cash returns to investors.
• ●Operational concentration risk: The company states that 80% or more of its revenue comes from a single hospital, increasing vulnerability to operational disruptions, regulatory changes, or local market shifts.

Bottom line

For investors, this announcement signals that FOXO Technologies is making real operational progress, with revenue growth and reduced operating losses in the most recent quarter. However, the majority of the upside touted by management is tied to future events—acquisitions, capital raises, and up-listings—that are not yet secured and carry significant execution and financing risk. The company's disclosures are sufficient to confirm headline improvements but fall short of providing the full financial transparency needed to assess long-term sustainability or value creation. The involvement of notable individuals like CEO Seamus Lagan and former CEO Jon Sabes (now a related-party licensee) suggests continuity but does not equate to external validation or guarantee institutional support. To materially change this assessment, FOXO would need to provide a full set of financial statements, segment-level profitability, and evidence of binding agreements for acquisitions or capital raises. Key metrics to watch in the next reporting period include realized revenue from new acquisitions, actual cash flow and net income, progress on up-listing, and any dilution or debt incurred to fund growth. At present, the signal is worth monitoring but not acting on aggressively: the operational improvements are real, but the investment case hinges on a series of unproven, capital-intensive steps that may or may not materialize. The single most important takeaway is that while FOXO is moving in the right direction operationally, the bulk of the investment thesis remains speculative and dependent on successful execution of ambitious, unfunded plans.

Announcement summary

(OTC: FOXOD) FOXO Technologies Inc. announced a mid-year update detailing achievements for the first six months of 2026, including reported net revenues of approximately $5.1 million for the three months ended March 31, 2026 compared to $3.2 million for the same period in 2025. The company reported a lower loss from operations in the first quarter, with a $0.3 million loss compared to a $1.5 million loss for the prior year’s comparable quarter. FOXO effected a 1:3,000 reverse stock split of its Class A common stock and exchanged approximately $7.8 million in stated value of Series A Convertible Preferred Stock into non-convertible debt. The company granted LongevityFP Technologies, LLC an exclusive, worldwide license to commercialize its epigenetics intellectual property portfolio, with a royalty equal to 3% of net revenues derived from commercialization of the Licensed IP, subject to an aggregate cap of $1,300,000. Myrtle Recovery Centers reported an average daily census of 27.6 (92% occupancy) and annualized patient admissions of approximately 700 for 2026, while Scott County Community Hospital is projected to see approximately 400 inpatient admissions and 65 swing bed admissions in 2026. The company projects that a potential acquisition in the Vector BioSource segment could add in excess of $10 million of annual revenues if completed in the second half of the year.

Disagree with this article?